Drug Profile

APG 157

Alternative Names: APG-157

Latest Information Update: 27 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Aveta Biomics
Class Antineoplastics
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II Head and neck cancer; Oropharyngeal dysplasia; Squamous cell cancer
Phase I/II Glioblastoma

Most Recent Events

14 Jan 2026 Aveta Biomics re-initiates a phase-II trial in Oropharyngeal dysplasia in USA (NCT05865028)
29 Dec 2025 Aveta Biomics terminates a phase-II trial in Oropharyngeal dysplasia in USA (NCT05865028)
17 Oct 2025 Efficacy and pharmacodynamics data from a phase IIa trial in Head and neck cancer presented at the 50^th European Society for Medical Oncology Congress (ESMO-2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com